PMID- 36761063
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230211
IS  - 2287-2892 (Print)
IS  - 2288-2561 (Electronic)
IS  - 2287-2892 (Linking)
VI  - 12
IP  - 1
DP  - 2023 Jan
TI  - Lipid Management in Korean People With Type 2 Diabetes Mellitus: Korean Diabetes 
      Association and Korean Society of Lipid and Atherosclerosis Consensus Statement.
PG  - 12-22
LID - 10.12997/jla.2023.12.1.12 [doi]
AB  - Dyslipidemia in patients with diabetes is an important treatment target as a 
      modifiable risk factor for cardiovascular disease (CVD). Although the primary 
      treatment goal for dyslipidemia is to control low-density lipoprotein cholesterol 
      (LDL-C), achieving this goal remains suboptimal according to recent studies. It 
      is important to set the target goal for LDL-C control based on an accurate risk 
      assessment for CVD. Here, we summarize the latest evidence on lipid management in 
      patients with diabetes and present a consensus of the Korean Diabetes Association 
      and Korean Society of Lipid and Atherosclerosis on the treatment goals of LDL-C 
      according to the duration of diabetes, presence of CVD, target organ damage, or 
      major cardiovascular risk factors. In patients with type 2 diabetes mellitus 
      (T2DM) and CVD, an LDL-C goal of <55 mg/dL and a reduction in LDL-C level by 50% 
      or more from the baseline is recommended. For the primary prevention of CVD in 
      patients with T2DM with a duration of diabetes >/=10 years, major cardiovascular 
      risk factors, or target organ damage, an LDL-C goal of <70 mg/dL is recommended. 
      In patients with T2DM with a duration of diabetes <10 years and no major 
      cardiovascular risk factors, an LDL-C goal of <100 mg/dL is recommended.
CI  - Copyright (c) 2023 The Korean Society of Lipid and Atherosclerosis.
FAU - Yang, Ye Seul
AU  - Yang YS
AUID- ORCID: 0000-0001-9682-6138
AD  - Department of Medicine, Seoul National University College of Medicine, Seoul, 
      Korea.
FAU - Kim, Hack-Lyoung
AU  - Kim HL
AUID- ORCID: 0000-0002-6703-1472
AD  - Department of Internal Medicine, Seoul Metropolitan Government-Seoul National 
      University Boramae Medical Center, Seoul, Korea.
AD  - Department of Internal Medicine, Seoul National University College of Medicine, 
      Seoul, Korea.
FAU - Kim, Sang-Hyun
AU  - Kim SH
AUID- ORCID: 0000-0001-8026-1582
AD  - Department of Internal Medicine, Seoul Metropolitan Government-Seoul National 
      University Boramae Medical Center, Seoul, Korea.
AD  - Department of Internal Medicine, Seoul National University College of Medicine, 
      Seoul, Korea.
FAU - Moon, Min Kyong
AU  - Moon MK
AUID- ORCID: 0000-0002-5460-2846
AD  - Department of Internal Medicine, Seoul Metropolitan Government-Seoul National 
      University Boramae Medical Center, Seoul, Korea.
AD  - Department of Internal Medicine, Seoul National University College of Medicine, 
      Seoul, Korea.
CN  - Committee of Clinical Practice Guideline, Korean Diabetes Association and 
      Clinical Practice Guideline Committee, Korean Society of Lipid and 
      Atherosclerosis
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230117
PL  - Korea (South)
TA  - J Lipid Atheroscler
JT  - Journal of lipid and atherosclerosis
JID - 101610890
PMC - PMC9884550
OTO - NOTNLM
OT  - Cholesterol, LDL
OT  - Diabetes mellitus, type 2
OT  - Dyslipidemias
OT  - Guideline
OT  - Hydroxymethylglutaryl-CoA reductase inhibitors
COIS- Conflict of Interest: The authors have no conflicts of interest to declare.
EDAT- 2023/02/11 06:00
MHDA- 2023/02/11 06:01
PMCR- 2023/01/01
CRDT- 2023/02/10 03:04
PHST- 2022/12/23 00:00 [received]
PHST- 2023/01/10 00:00 [accepted]
PHST- 2023/02/10 03:04 [entrez]
PHST- 2023/02/11 06:00 [pubmed]
PHST- 2023/02/11 06:01 [medline]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.12997/jla.2023.12.1.12 [doi]
PST - ppublish
SO  - J Lipid Atheroscler. 2023 Jan;12(1):12-22. doi: 10.12997/jla.2023.12.1.12. Epub 
      2023 Jan 17.